Key Financial

In 2023, Angelini Pharma consolidated revenues of €1,220.9 million (+3.5% vs 2022), with 49% generated in international markets, achieving an EBITDA of €243.8 million (+12.2% vs 2022) and an EBITDA margin of 20% (18.4% in 2022): growth reflecting a commitment to innovation and quality care. 

During the year, the launch of cenobamate, an innovative antiepileptic molecule, was completed in major European countries, and today the company offers therapeutic solutions for three major Brain Health disorders (epilepsy, schizophrenia, and depression).

In 2023, Angelini Pharma also signed an exclusive agreement with JCR Pharmaceuticals aimed at developing new biological therapies for epilepsy treatment. This agreement allows for the exploration of new therapeutic frontiers, confirming Angelini Industries' ambitious investment strategy in the pharmaceutical sector.

Driven by strong ethics, responsibility, and innovation, Angelini Pharma aims to improve patients' quality of life through investments, research, and ongoing awareness activities about diseases.